Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Solid Tumor × nimotuzumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Nasopharyngeal Carcinoma 18 Esophageal Squamous Cell Carcinoma 11 Esophageal Neoplasms 11 Uterine Cervical Neoplasms 8 Squamous Cell Carcinoma of Head and Neck 8 Pancreatic Neoplasms 8 Carcinoma, Non-Small-Cell Lung 8 Head and Neck Neoplasms 6 Stomach Neoplasms 3 Neoplasms 3 Recurrence 2 Pancreatic cancer, adult 2 Neoplasm Metastasis 2 Nasopharyngeal Neoplasms 2 Lung Neoplasms 2 Diffuse Intrinsic Pontine Glioma 2 Colorectal Neoplasms 2 Carcinoma 2 Adenocarcinoma 2 Uterine Cervical Dysplasia 1 Urinary Bladder Neoplasms 1 Squamous Cell Carcinoma of Anal Canal 1 Solid Tumors 1 Solid Tumor 1 Resectable Pancreatic Cancer 1 Penile Neoplasms 1 Pancreatic Cancer Resectable 1 Oropharyngeal Neoplasms 1 Nasopharyngeal Diseases 1 NSCLC 1

Interventions

pembrolizumab 12 Injections 12 Paclitaxel 10 Docetaxel 9 Cisplatin 8 Capecitabine 8 senaparib 7 Nivolumab 7 Fluorodeoxyglucose F18 7 Bevacizumab 7 toripalimab 6 atezolizumab 6 Irinotecan 6 Fluorouracil 6 Cyclophosphamide 6 tislelizumab 5 fludarabine 4 apatinib 4 Leucovorin 4 Ipilimumab 4 Gemcitabine 4 spartalizumab 3 pertuzumab 3 olaparib 3 camrelizumab 3 Rifampin 3 Radiosurgery 3 Oxaliplatin 3 Midazolam 3 Itraconazole 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06022276 2023-09-01

Nimotuzumab for EGFR-amplified Advanced Pan Solid Tumors

Tianjin Medical University Second Hospital

Phase NA Unknown

Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡